Approved LXR agonists exert unspecific effects on pancreatic β-cell function
Open Access
- 7 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Endocrine
- Vol. 68 (3), 526-535
- https://doi.org/10.1007/s12020-020-02241-4
Abstract
Novel agonists of the nuclear liver-X-receptor (LXR) are designed to treat metabolic disorders or cancer. The rationale to develop these new drugs is based on promising results with established LXR agonist like T0901317 and GW3965. LXRα and LXRβ are expressed in β-cells, and expression is increased by T0901317. The aim of the present study was to evaluate whether effects of these drugs on β-cell function are specific and reliably linked to LXR activation. T0901317 and GW3965, widely used as specific LXR agonists, show rapid, non-genomic effects on stimulus-secretion coupling of mouse pancreatic β-cells at low µM concentrations. T0901317 lowered the cytosolic Ca2+ concentration, reduced or completely inhibited action potentials, and decreased insulin secretion. GW3965 exerted similar effects on insulin secretion. T0901317 affected the production of reactive oxygen species and ATP. The involvement of the classical nuclear LXRs in T0901317- and GW3965-mediated effects in β-cells could be ruled out using LXRα, LXRβ and double knockout mice. Our results strongly suggest that LXR agonists, that are considered to be specific for this receptor, interfere with mitochondrial metabolism and metabolism-independent processes in β-cells. Thus, it is indispensable to test novel LXR agonists accompanying to ongoing clinical trials for acute and chronic effects on cell function in cellular systems and/or animal models lacking classical LXRs.Funding Information
- Deutsche Forscungsgemeinschaft (Dr225/11-1)
This publication has 39 references indexed in Scilit:
- Activation of the Liver X Receptor by Agonist TO901317 Improves Hepatic Insulin Resistance via Suppressing Reactive Oxygen Species and JNK PathwayPLOS ONE, 2015
- Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db miceCardiovascular Diabetology, 2014
- Activation of Liver-X-Receptor α But Not Liver-X-Receptor β Protects Against Myocardial Ischemia/Reperfusion InjuryCirculation: Heart Failure, 2014
- Insulin-Sensitizing Effect of LXR Agonist T0901317 in High-Fat Fed Rats is Associated with Restored Muscle GLUT4 Expression and Insulin-Stimulated AS160 PhosphorylationCellular Physiology and Biochemistry, 2013
- Liver-X-receptor activator prevents homocysteine-induced production of IgG antibodies from murine B lymphocytes via the ROS–NF-κB pathwayBiochemical and Biophysical Research Communications, 2007
- Cholesterol oxides as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitusDiabetes/Metabolism Research and Reviews, 2006
- Putative Metabolic Effects of the Liver X Receptor (LXR)Diabetes, 2004
- The LXRs: a new class of oxysterol receptorsCurrent Opinion in Genetics & Development, 1998
- Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRαCell, 1998
- An oxysterol signalling pathway mediated by the nuclear receptor LXRαNature, 1996